Share on LinkedInShare on LinkedIn

ARTICLE · 22 MARCH 2022

Possession Of An "Effective" Dose

Morrison Foerster
Morrison Foerster
Contributor
Morrison Foerster

Morrison Foerster

With approximately 1,000 lawyers in 19 offices, Morrison & Foerster is a preeminent global law firm...

View firm profile
Explore more from Morrison Foerster

Update: On March 16, 2022, the U.S. Court of Appeals for the Federal Circuit denied Biogen International's petition for panel rehearing and rehearing en banc...

United StatesIntellectual Property

Update: On March 16, 2022, the U.S. Court of Appeals for the Federal Circuit denied Biogen International's petition for panel rehearing and rehearing en banc, following a November split decision discussed below.

Judges Lourie, Moore, and Newman dissented on the denial of en banc rehearing. Judge O'Malley had dissented from the November panel decision, but retired on March 11, 2022 and only participated in the decision on panel rehearing, not the decision on rehearing en banc.

The dissent indicates that the court remains divided regarding application of the written description requirement to the facts in this case.

When does an applicant have "enough" to file a patent application and be granted a patent?

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

See more popular content from